How much revenue did Incyte generate this year?
Incyte has achieved a revenue of 4.29 B USD this year.
Incyte Revenue 2024
Incyte Revenue
4.29 B USD
Ticker
INCY
ISIN
US45337C1027
WKN
896133
In 2024, Incyte's sales reached 4.29 B USD, a 16.08% difference from the 3.7 B USD sales recorded in the previous year.
The Incyte Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 4.07 | 85,19 |
| 2028e | 6.02 | 57,54 |
| 2027e | 5.68 | 61,02 |
| 2026e | 5.24 | 66,10 |
| 2025e | 4.73 | 73,20 |
| 2024e | 4.29 | 80,73 |
| 2023 | 3.7 | 93,71 |
| 2022 | 3.39 | 94,54 |
| 2021 | 2.99 | 95,66 |
| 2020 | 2.67 | 95,88 |
| 2019 | 2.16 | 95,70 |
| 2018 | 1.88 | 96,14 |
| 2017 | 1.54 | 96,22 |
| 2016 | 1.11 | 95,88 |
| 2015 | 0.75 | 96,42 |
| 2014 | 0.51 | 99,41 |
| 2013 | 0.35 | 99,83 |
| 2012 | 0.3 | 99,93 |
| 2011 | 0.09 | 3664,72 |
| 2010 | 0.17 | 2038,35 |
| 2009 | 0.01 | 37238,27 |
| 2008 | 0 | 88798,95 |
| 2007 | 0.03 | 10067,32 |
| 2006 | 0.03 | 12547,68 |
| 2005 | 0.01 | 44399,47 |
| 2004 | 0.01 | 24561,41 |
Incyte Revenue, EBIT, Net Income US45337C1027 · 896133
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Incyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Incyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Incyte’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Incyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Incyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Incyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Incyte’s growth potential.
Incyte Revenue, EBIT and net profit per share
| Date | Incyte Revenue | Incyte EBIT | Incyte Net Income |
|---|---|---|---|
| 2029e | 4.07 B undefined | 838.19 M undefined | 882.02 M undefined |
| 2028e | 6.02 B undefined | 2.18 B undefined | 1.98 B undefined |
| 2027e | 5.68 B undefined | 2.01 B undefined | 1.77 B undefined |
| 2026e | 5.24 B undefined | 1.86 B undefined | 1.52 B undefined |
| 2025e | 4.73 B undefined | 1.45 B undefined | 1.21 B undefined |
| 2024e | 4.29 B undefined | 376.92 M undefined | 256.6 M undefined |
| 2023 | 3.7 B undefined | 651.77 M undefined | 597.6 M undefined |
| 2022 | 3.39 B undefined | 599.5 M undefined | 340.7 M undefined |
| 2021 | 2.99 B undefined | 637.6 M undefined | 948.6 M undefined |
| 2020 | 2.67 B undefined | -197.5 M undefined | -295.7 M undefined |
| 2019 | 2.16 B undefined | 421.7 M undefined | 446.9 M undefined |
| 2018 | 1.88 B undefined | 155.4 M undefined | 109.5 M undefined |
| 2017 | 1.54 B undefined | -235.7 M undefined | -313.1 M undefined |
| 2016 | 1.11 B undefined | 162.4 M undefined | 104.2 M undefined |
| 2015 | 753.8 M undefined | 50.7 M undefined | 6.5 M undefined |
| 2014 | 511.5 M undefined | -4.8 M undefined | -48.5 M undefined |
| 2013 | 354.9 M undefined | -16.1 M undefined | -83.1 M undefined |
| 2012 | 297.1 M undefined | 1.1 M undefined | -44.3 M undefined |
| 2011 | 94.5 M undefined | -142.5 M undefined | -186.5 M undefined |
| 2010 | 169.9 M undefined | 13.7 M undefined | -31.8 M undefined |
| 2009 | 9.3 M undefined | -137.8 M undefined | -211.9 M undefined |
| 2008 | 3.9 M undefined | -159.5 M undefined | -178.9 M undefined |
| 2007 | 34.4 M undefined | -85.7 M undefined | -86.9 M undefined |
| 2006 | 27.6 M undefined | -76.9 M undefined | -74.2 M undefined |
| 2005 | 7.8 M undefined | -99.4 M undefined | -103 M undefined |
| 2004 | 14.1 M undefined | -148.9 M undefined | -164.8 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 14.1 M USD | -148.9 M USD | -164.8 M USD |
| 2005 | 7.8 M USD | -99.4 M USD | -103 M USD |
| 2006 | 27.6 M USD | -76.9 M USD | -74.2 M USD |
| 2007 | 34.4 M USD | -85.7 M USD | -86.9 M USD |
| 2008 | 3.9 M USD | -159.5 M USD | -178.9 M USD |
| 2009 | 9.3 M USD | -137.8 M USD | -211.9 M USD |
| 2010 | 169.9 M USD | 13.7 M USD | -31.8 M USD |
| 2011 | 94.5 M USD | -142.5 M USD | -186.5 M USD |
| 2012 | 297.1 M USD | 1.1 M USD | -44.3 M USD |
| 2013 | 354.9 M USD | -16.1 M USD | -83.1 M USD |
| 2014 | 511.5 M USD | -4.8 M USD | -48.5 M USD |
| 2015 | 753.8 M USD | 50.7 M USD | 6.5 M USD |
| 2016 | 1.11 B USD | 162.4 M USD | 104.2 M USD |
| 2017 | 1.54 B USD | -235.7 M USD | -313.1 M USD |
| 2018 | 1.88 B USD | 155.4 M USD | 109.5 M USD |
| 2019 | 2.16 B USD | 421.7 M USD | 446.9 M USD |
| 2020 | 2.67 B USD | -197.5 M USD | -295.7 M USD |
| 2021 | 2.99 B USD | 637.6 M USD | 948.6 M USD |
| 2022 | 3.39 B USD | 599.5 M USD | 340.7 M USD |
| 2023 | 3.7 B USD | 651.77 M USD | 597.6 M USD |
| 2024e | 4.29 B USD | 376.92 M USD | 256.6 M USD |
| 2025e | 4.73 B USD | 1.45 B USD | 1.21 B USD |
| 2026e | 5.24 B USD | 1.86 B USD | 1.52 B USD |
| 2027e | 5.68 B USD | 2.01 B USD | 1.77 B USD |
| 2028e | 6.02 B USD | 2.18 B USD | 1.98 B USD |
| 2029e | 4.07 B USD | 838.19 M USD | 882.02 M USD |
Incyte stock margins US45337C1027 · 896133
The Incyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Incyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Incyte.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Incyte's sales revenue. A higher gross margin percentage indicates that the Incyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Incyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Incyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Incyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Incyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Incyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Incyte Margin History
| Incyte Gross margin | Incyte Profit margin | Incyte EBIT margin | Incyte Profit margin |
|---|---|---|---|
| 2029e | 93.71 % | 20.62 % | 21.7 % |
| 2028e | 93.71 % | 36.25 % | 32.94 % |
| 2027e | 93.71 % | 35.33 % | 31.16 % |
| 2026e | 93.71 % | 35.58 % | 29.04 % |
| 2025e | 93.71 % | 30.71 % | 25.5 % |
| 2024e | 93.71 % | 8.79 % | 5.98 % |
| 2023 | 93.71 % | 17.64 % | 16.17 % |
| 2022 | 94.54 % | 17.66 % | 10.04 % |
| 2021 | 95.66 % | 21.35 % | 31.77 % |
| 2020 | 95.88 % | -7.41 % | -11.09 % |
| 2019 | 95.7 % | 19.53 % | 20.7 % |
| 2018 | 96.14 % | 8.26 % | 5.82 % |
| 2017 | 96.22 % | -15.34 % | -20.38 % |
| 2016 | 95.88 % | 14.69 % | 9.42 % |
| 2015 | 96.42 % | 6.73 % | 0.86 % |
| 2014 | 99.41 % | -0.94 % | -9.48 % |
| 2013 | 99.83 % | -4.54 % | -23.42 % |
| 2012 | 99.93 % | 0.37 % | -14.91 % |
| 2011 | 93.71 % | -150.79 % | -197.35 % |
| 2010 | 93.71 % | 8.06 % | -18.72 % |
| 2009 | 93.71 % | -1,481.72 % | -2,278.49 % |
| 2008 | 93.71 % | -4,089.74 % | -4,587.18 % |
| 2007 | 93.71 % | -249.13 % | -252.62 % |
| 2006 | 93.71 % | -278.62 % | -268.84 % |
| 2005 | 93.71 % | -1,274.36 % | -1,320.51 % |
| 2004 | 93.71 % | -1,056.03 % | -1,168.79 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 93.71 % | -1,056.03 % | -1,168.79 % |
| 2005 | 93.71 % | -1,274.36 % | -1,320.51 % |
| 2006 | 93.71 % | -278.62 % | -268.84 % |
| 2007 | 93.71 % | -249.13 % | -252.62 % |
| 2008 | 93.71 % | -4,089.74 % | -4,587.18 % |
| 2009 | 93.71 % | -1,481.72 % | -2,278.49 % |
| 2010 | 93.71 % | 8.06 % | -18.72 % |
| 2011 | 93.71 % | -150.79 % | -197.35 % |
| 2012 | 99.93 % | 0.37 % | -14.91 % |
| 2013 | 99.83 % | -4.54 % | -23.42 % |
| 2014 | 99.41 % | -0.94 % | -9.48 % |
| 2015 | 96.42 % | 6.73 % | 0.86 % |
| 2016 | 95.88 % | 14.69 % | 9.42 % |
| 2017 | 96.22 % | -15.34 % | -20.38 % |
| 2018 | 96.14 % | 8.26 % | 5.82 % |
| 2019 | 95.7 % | 19.53 % | 20.7 % |
| 2020 | 95.88 % | -7.41 % | -11.09 % |
| 2021 | 95.66 % | 21.35 % | 31.77 % |
| 2022 | 94.54 % | 17.66 % | 10.04 % |
| 2023 | 93.71 % | 17.64 % | 16.17 % |
| 2024e | 93.71 % | 8.79 % | 5.98 % |
| 2025e | 93.71 % | 30.71 % | 25.5 % |
| 2026e | 93.71 % | 35.58 % | 29.04 % |
| 2027e | 93.71 % | 35.33 % | 31.16 % |
| 2028e | 93.71 % | 36.25 % | 32.94 % |
| 2029e | 93.71 % | 20.62 % | 21.7 % |
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
82 % Product
14 % Product Royalty
4 % Milestone & Contract
Revenue Details
Understanding Incyte's Sales Figures
The sales figures of Incyte originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Incyte’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Incyte's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Incyte’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Incyte stock
How much was the turnover of the company Incyte compared to the previous year?
The revenue of Incyte has increased by 16.08% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Incyte?
The revenue of Incyte is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Incyte measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Incyte so important for investors?
The revenue of Incyte is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
